CAR T Cell Therapy in China
Empowering Immunity, Defeating Cancer — Experience the Future of CAR-T Therapy in China.
What Is CAR-T Cell Therapy?
CAR-T cell therapy, short for Chimeric Antigen Receptor T-cell therapy, is one of the most groundbreaking innovations in modern cancer immunotherapy. This advanced treatment harnesses the patient’s own immune system by collecting T-cells and genetically engineering them to express special receptors (CARs) that can precisely identify and destroy cancer cells.
After years of extensive clinical research, China has become one of the world’s leading countries in the development and application of CAR-T cell therapies. With eight products approved by the National Medical Products Administration (NMPA), Chinese biotechnology firms and top hospitals are delivering therapies that have achieved exceptional remission rates in blood cancers such as leukemia, lymphoma, and multiple myeloma.
Today, China’s CAR-T research is expanding beyond hematologic malignancies, exploring new frontiers in treating solid tumors — including liver, lung, and pancreatic cancers — as well as autoimmune diseases such as lupus and multiple sclerosis. By retraining the body’s own immune system to attack abnormal cells with precision and control, CAR-T cell therapy represents a transformative leap forward in personalized medicine and immune-based treatment.
Who Is CAR-T Cell Therapy For?
CAR-T cell therapy is primarily designed for patients with relapsed or refractory blood cancers — such as leukemia, lymphoma, or multiple myeloma — who have not achieved lasting results from conventional treatments like chemotherapy, radiation therapy, or stem cell transplantation. Approved and investigational CAR-T therapies in China target a wide range of cancers and autoimmune diseases, including:
- Multiple Myeloma (MM)
- Large B-cell Lymphoma (LBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Pediatric B-Cell Acute Lymphoblastic Leukemia
China currently hosts one of the world’s largest networks of CAR-T clinical trials, investigating its potential across an expanding list of conditions — from blood cancers to solid tumors and immune-mediated diseases. These efforts are rapidly advancing the global understanding of how CAR-T therapy can be safely and effectively applied in diverse medical fields.
World-class Technology
A global leader in CAR-T technology research, development and clinical application.
Streamlined Access
Faster eligibility screening and hospital matching, with access to clinical trials and approved therapies not yet available in your home country. Cell manufacturing typically takes 3–4 weeks.y.
Experienced Experts
The most experienced medical professionals in managing CAR-T cell therapy and comprehensive protocols.
Transparent Pricing
Clear cost breakdown across three pathways: approved product (USD 100K–250K), clinical trial (drug may be free), and unregistered (not recommended). No hidden hospital commissions.
What makes China the best destination for CAR-T cell therapy?
With advanced technology, internationally recognized specialists, and growing accessibility for international patients, China has become one of the most promising destinations for receiving CAR-T cell therapy.
The development of CAR T-cell therapy in China has advanced rapidly, fueled by significant government investment and a robust biotechnology sector. Chinese companies have been at the forefront of innovating cost-effective manufacturing processes, making CAR T-cell therapy more affordable and accessible. Several CAR T-cell therapies developed in China have received regulatory approvals and are being used to treat patients domestically and internationally. Additionally, collaborations between Chinese researchers and global institutions continue to drive innovations, positioning China as a leader in this cutting-edge medical field.
China has rapidly emerged as a global leader in CAR-T cell research and treatment, with over hundreds of clinical trials, advanced manufacturing facilities, and government support for biotech innovation.
For eligible patients, especially those facing financial or access barriers, traveling to China for CAR-T therapy may open the door to life-saving treatment. With China’s growing expertise and affordability, it is becoming an essential destination in the global fight against cancer.
NMPA-Approved CD19 CAR-T in China: Relma-cel (CARTEYVA®)
China has approved CD19-directed CAR-T products for B-cell lymphomas. Among them is Relma-cel (brand name CARTEYVA®, developed by JW Therapeutics), approved by the NMPA for relapsed/refractory B-cell non-Hodgkin lymphoma.
Relma-cel (CARTEYVA®) Overview
CD19 (expressed on B-cell lymphomas)
r/r Diffuse Large B-Cell Lymphoma (LBCL), r/r Follicular Lymphoma (FL), r/r Mantle Cell Lymphoma (MCL)
4-1BB co-stimulatory domain + CD28/IgG4 optimized hinge — designed for high efficacy with lower toxicity
GMP-certified facility, purified T cells (clinical purity ~99%) for product consistency and safety
About the product: Relma-cel is built on a CAR engineering platform shared with a globally approved CD19 CAR-T, combining 4-1BB costimulation (associated with lower CRS rates and longer persistence) with an optimized hinge region. China's extensive real-world experience spans large patient volumes across approved and clinical settings.
CAR-T in China: Frequently Asked Questions
Last updated: August 2026 · For educational purposes only, not medical advice.
Start Planning Your Medical Journey
Traveling abroad for medical treatment can feel overwhelming, particularly when dealing with insurance procedures and unfamiliar healthcare systems.
Medical Tourism China serves as your support partner, connecting you with leading hospitals and experienced medical specialists while helping coordinate the administrative details along the way.
Contact our team today to learn more about insurance coverage, direct billing possibilities, and treatment options in China.
CIHA-ACCREDITED HOSPITALS
JCI-ACCREDITED HOSPITALS
GMP-CERTIFIED FACILITIES
